YONGIN, South Korea, July 21, 2024 /PRNewswire/ — GC Cell Company (hereinafter known as “GC Cell“; 144510:KOSDAQ) and Lukas Biomedical Co., Ltd. (hereinafter known as “Lukas,” TWSE 6814) has formally signed a world strategic cooperation settlement.
GC Cell is a completely built-in pioneer in cell and gene remedy and a subsidiary of the famend Korean-listed pharmaceutical group Inexperienced Cross Company, which has a market worth of roughly 1.3 trillion Korean received (round 1 billion US {dollars}).
This collaboration goals to extend consciousness of autologous T cell remedy in addition to to develop the affected person entry market by way of leveraging one another’s strengths in revolutionary cell remedy areas. By sharing cutting-edge analysis initiatives, medical trial knowledge, regulatory information throughout a number of nations, and exploring medical analysis, market improvement, and numerous actions for cancers and different difficult illnesses, each events try to speed up drug improvement and set up a platform for precision drugs options. This partnership seeks to carry the advantages of revolutionary cell remedy to a wider vary of sufferers.
Having efficiently accomplished medical trials in Japan and Korea, GC Cell’s Immuncell-LC autologous T cell remedy obtained approval from the Ministry of Meals and Drug Security (MFDS) in 2007 following favorable Section IV trials. With a observe report of over 10,000 remedy instances, GC Cell has been acquiring profitable medical and business data in Korea. Lukas’s LuLym-T reminiscence T cell cultivation know-how originated from Japanese Nationwide Most cancers Middle and GC LTEC, previously Lymphotec, a subsidiary of Inexperienced Cross Group. Primarily based on the licensing settlement with originator of the know-how and the tech switch from the corporate, Lukas has introduced this know-how to Taiwan for market growth and additional enhancement.
Taiwan’s authorities has demonstrated vital dedication to the development of the regenerative drugs sector. Following the implementation of the Particular Laws on Regenerative Drugs, the Regenerative Drugs Act was enacted on June 4 this yr. Lukas’s LuLym-T cell remedy know-how, supported by worldwide medical trials and evidence-based knowledge generated by GC Cell, aligns intently with Taiwan governmental insurance policies and laws. It seems poised to safe a five-year conditional approval below the brand new laws, thus establishing Lukas as a distinguished participant in Taiwan’s cell remedy panorama, with a give attention to home development and world market growth. Presently, Lukas has entered agreements with 13 medical establishments, together with Nationwide Taiwan College Hospital, Chang Gung Memorial Hospital, and Taipei Veterans Basic Hospital, to conduct Section II medical trials centered on stopping liver most cancers recurrence and exploring mixed immunotherapy with chemotherapy/radiotherapy for head and neck most cancers at Taipei Veterans Basic Hospital.
Lukas’ Chairman, Dr. Eric Tang, highlighted that GC Cell and Lukas will collaborate by way of a Joint Committee (JC) to alternate experience and expertise in researching reminiscence T cell know-how for numerous cancers of their respective nations. This collaboration includes sharing medical and business information, insights, and methods, in addition to exploring alternatives for cross-licensing and conducting joint medical trials (IITs and SITs) in one another’s areas. Furthermore, they purpose to debate the alternatives to collectively discover new worldwide markets, joint funding and past.
James Park, CEO of GC Cell, acknowledged, “This strategic cooperation agreement represents a pivotal milestone in accelerating the advancement of innovative cell therapies in Korea and Taiwan and also in establishing global network and ecosystem of Cell and Gene Therapy. Looking ahead, we are committed to accelerating the global expansion of Immuncell-LC through the continuous exchange of clinical research data and the establishment of a strong, long-term partnership between our two companies.”
Dr. Eric Tang, Chairman of Lukas acknowledged that: “In addition to our clinical trial for preventing liver cancer recurrence, the Taiwanese government’s implementation of the Special Regulations on Regenerative Medicine has allowed us to apply our LuLym-T cell technology on advanced stage cancer patients with various types of solid tumors. We have accumulated vast clinical experience in concomitant use of LuLym-T cell together with conventional treatment, such as: chemotherapy, radiotherapy, and checkpoint inhibitors. We are able to achieve significant prognostic improvements using a multi-modality treatment paradigm for advanced stage cancers and we hope we will be able to help more cancer patients in need by sharing our experience with other countries”.
This strategic cooperation represents a major step towards a shared imaginative and prescient of bettering affected person outcomes by way of revolutionary cell therapies and precision drugs.
About Immuncell-LC
Immuncell-LC is the one commercially obtainable remedy possibility of early-stage HCC. It’s primarily composed of autologous, cultured blood-derived T lymphocytes with confirmed efficacy by way of a large-scale Section 3 medical trial which decreased the chance of recurrence by 37% and decreased the mortality charge by 79% in comparison with the management group. Thus far, Immuncell-LC has been administered to over 10,000 sufferers in South Korea with out critical opposed occasions.¯
About GC Cell¯¯
With a core give attention to cell remedy, GC Cell affords full bio healthcare options from prognosis to remedy, and the model’s complete worth chain spans R&D, manufacturing, commercialization, and distribution.
Extra data: https://gccell.com/
About Lukas Biomedical
Lukas is devoted to advancing its LuLym-T cell remedy R&D and medical developments, enhancing medical trials and applied sciences, and increasing into international markets. Lukas has already attracted curiosity in Southeast Asia and is in talks and finalizing cooperation agreements with medical groups within the area. With a gentle money movement from its e-commerce enterprise and hospital administration platform, Lukas is well-positioned to develop its “LuLym-T” cell remedy enterprise and, producing optimum worth for shareholders and staff.
